Renovaro BioSciences has announced a letter of intent to merge a subsidiary with Gedi Cube, a company focused on artificial intelligence offerings.
Los Angeles-based Renovaro is a pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy.
The deal would be beneficial because Gedi Cube’s AI technology could potentially enable the combined company to focus upcoming human trials on the cancers most likely to respond to therapy, expand the database of key markers for earlier diagnosis and disease progression and discover new generations of Renovaro’s treatment approach as well as entirely new therapies.
"Renovaro, Latin for 'renewal,' represents our company’s mission,” Renovaro Biosciences CEO Dr. Mark Dybul said. “Our advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms. I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families.”
Healthcare is embracing artificial intelligence. Pharma companies are finding comfort in AI because it could cut drug development costs and timeframes by sorting through and evaluating candidates, according to an article from Bloomberg. And recently, health officials in the UK launched an ambitious plan to use AI to help diagnose stroke, cancer, and heart conditions. The plan included an investment of £21 million.
